Q3 2024 Earnings Estimate for Solid Biosciences Inc. (NASDAQ:SLDB) Issued By HC Wainwright

Solid Biosciences Inc. (NASDAQ:SLDB) – Investment analysts at HC Wainwright upped their Q3 2024 earnings per share estimates for shares of Solid Biosciences in a research note issued on Wednesday, August 14th. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($0.70) for the quarter, up from their previous estimate of ($0.74). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q4 2024 earnings at ($0.73) EPS, FY2024 earnings at ($2.68) EPS, Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.49) EPS, FY2026 earnings at ($2.94) EPS, FY2027 earnings at ($2.26) EPS and FY2028 earnings at ($0.90) EPS.

Several other analysts have also issued reports on SLDB. Piper Sandler reissued an “overweight” rating and set a $20.00 price target on shares of Solid Biosciences in a report on Friday, June 21st. SVB Leerink upgraded Solid Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 price objective on the stock in a research report on Monday, June 24th. JPMorgan Chase & Co. raised Solid Biosciences from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $10.00 to $15.00 in a research note on Monday, July 15th. Leerink Partnrs raised shares of Solid Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 24th. Finally, Barclays dropped their target price on shares of Solid Biosciences from $18.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $15.67.

Solid Biosciences Trading Down 0.7 %

Shares of SLDB stock opened at $8.87 on Friday. The firm’s 50 day moving average is $7.61 and its 200 day moving average is $9.10. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.94 and a current ratio of 14.94. Solid Biosciences has a 12-month low of $1.81 and a 12-month high of $15.05.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.61) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.05.

Institutional Investors Weigh In On Solid Biosciences

Several large investors have recently added to or reduced their stakes in SLDB. Vestal Point Capital LP acquired a new position in Solid Biosciences in the fourth quarter valued at $209,000. Vanguard Group Inc. raised its stake in Solid Biosciences by 283.9% during the 1st quarter. Vanguard Group Inc. now owns 1,244,575 shares of the company’s stock valued at $16,578,000 after acquiring an additional 920,404 shares during the last quarter. Bain Capital Life Sciences Investors LLC lifted its position in Solid Biosciences by 28.9% during the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 4,034,582 shares of the company’s stock worth $53,741,000 after acquiring an additional 904,160 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Solid Biosciences in the first quarter valued at approximately $23,935,000. Finally, Artal Group S.A. lifted its holdings in shares of Solid Biosciences by 175.0% during the first quarter. Artal Group S.A. now owns 2,500,000 shares of the company’s stock worth $33,300,000 after purchasing an additional 1,590,781 shares during the period. 81.46% of the stock is owned by hedge funds and other institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.